Since the FOXM1 pathway has a high positive activity score (i.e., activated) in BC while a high negative activity score (i.e., inactivated) in normal breast tissue, an effective drug treatment should reduce the FOXM1 pathway activity score (i.e., suppressing the pathway activity) and thus have a larger negative activity score difference (ASd) between treatment and control groups. This evidence concerns the gene FOXM1 and breast cancer.